Avenue Therapeutics Announces Publication of Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that a publication titled “Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis” has been published in
Drug and Alcohol Dependence, a peer-reviewed international journal devoted to research, reviews, commentaries, and policy analyses in the area of drug, alcohol and tobacco use and dependence. The publication can be accessed here.
“The goal of the study is to better understand the misuse and abuse of tramadol in countries where parenteral tramadol is available, which requires consistent measures of misuse behaviors and prevalence between countries. We evaluated tramadol compared to conventional opioids by utilizing a harmonized validated n